List view / Grid view
The investigational SARS-CoV-2 vaccine developed by J&J is now due…
The investigational SARS-CoV-2 vaccine developed by J&J is now due to start its Phase I/IIa clinical trial at the end of July.
Developed by Janssen, the two-dose regimen has already been given…
Developed by Janssen, the two-dose regimen has already been given to 60,000 patients and now has the positive opinion of the Committee for Medicinal Products for Human Use (CHMP).
Following the selection of a COVID-19 vaccine lead, Johnson &…
Following the selection of a COVID-19 vaccine lead, Johnson & Johnson (J&J) aims to begin clinical trials in humans later this year while also scaling up its manufacturing facilities.
Johnson & Johnson announced Janssen Pharmaceutical Companies will work collaboratively…
Johnson & Johnson announced Janssen Pharmaceutical Companies will work collaboratively to screen for antiviral therapies and vaccine therapies against 2019-nCoV.
Johnson & Johnson has announced that it will be contributing…
Johnson & Johnson has announced that it will be contributing vaccines to support the Rwandan immunisation programme to combat Ebola.
